Short-term impact of delayed surgical treatment on the prognosis of patients with T1bN1-stage PTC: a retrospective cohort study
- PMID: 40426087
- PMCID: PMC12107860
- DOI: 10.1186/s12885-025-14371-x
Short-term impact of delayed surgical treatment on the prognosis of patients with T1bN1-stage PTC: a retrospective cohort study
Abstract
Background: As the incidence of papillary thyroid carcinoma (PTC) increases, optimal timing for surgical interventions remains undefined. While surgical delays are known to affect prognosis adversely in various cancers, their impact on PTC is controversial.
Methods: A retrospective study was conducted on 478 T1bN1-stage PTC patients treated at West China Hospital from January 2020 to May 2022. Patients underwent thyroidectomy with lymph node dissection and were categorized into three groups based on surgical delay: ≤90 days (group A, n = 264), > 90-180 days (group B, n = 92), and > 180 days (group C, n = 122). Additionally, patients were reclassified into two groups based on a one-year threshold: ≤365 days (group D, n = 420) and > 365 days (group E, n = 58). Tumor metastasis rates and postoperative complications were analyzed across these groups.
Results: The median surgical delay was 79 days, and the median follow-up was 1362 days. Tumor metastasis occurred in 1.67% (8 patients), while postoperative complications occurred in 5.65% (27 patients). Metastasis rates were 1.89%, 1.09%, and 1.64%, and complication rates were 5.68%, 4.35%, and 6.56% for groups A, B, and C, respectively. No statistically significant differences were observed in metastasis or complication rates among the three groups. Similarly, no significant differences were found between groups D and E in tumor metastasis (p = 1.000) or complication rates (p = 0.555).
Conclusion: Delayed surgery was not associated with significantly increased short-term tumor metastasis or postoperative complication rates in patients with T1bN1-stage PTC.
Keywords: Delayed surgery; Papillary thyroid carcinoma; Postoperative complications.; T1bN1-stage; Tumor metastasis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This retrospective cohort study was conducted in accordance with the Declaration of Helsinki and received approval from the the Biomedical Ethics Review Committee of West China Hospital, Sichuan University (2024 [2051]), and registration was completed with the Chinese Clinical Trial Registry (ChiCTR2500095113). Given the retrospective nature of the study and the use of anonymized data, the ethics committee waived the requirement for informed consent. Patient data were de-identified prior to analysis to ensure confidentiality and protect privacy. The study was conducted in compliance with local legislation and relevant guidelines. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Thyroid lobectomy for unilateral TNM T1 and T2 papillary thyroid carcinoma patients with lateral lymph node metastasis.Surgery. 2025 Apr;180:109028. doi: 10.1016/j.surg.2024.109028. Epub 2024 Dec 30. Surgery. 2025. PMID: 39740604
-
Recurrence and Complications in Pediatric and Adolescent Papillary Thyroid Cancer in a High-Volume Practice.J Surg Res. 2020 May;249:58-66. doi: 10.1016/j.jss.2019.12.002. Epub 2020 Jan 7. J Surg Res. 2020. PMID: 31923715
-
A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma.Surgery. 2022 Jan;171(1):182-189. doi: 10.1016/j.surg.2021.03.071. Epub 2021 Aug 12. Surgery. 2022. PMID: 34391573 Clinical Trial.
-
Prophylactic central lymph node dissection in cN0 papillary thyroid cancer: a comparative study of via breast and transoral approach versus via breast approach alone.Front Endocrinol (Lausanne). 2024 May 7;15:1356739. doi: 10.3389/fendo.2024.1356739. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38774230 Free PMC article.
-
Decoding lymph node skip metastasis: impact on long-term outcomes in stage T1 papillary thyroid carcinoma.Eur J Endocrinol. 2025 Mar 3;192(3):318-326. doi: 10.1093/ejendo/lvaf050. Eur J Endocrinol. 2025. PMID: 40088464
References
-
- Huang J, Ngai CH, Deng Y, et al. Incidence and mortality of thyroid cancer in 50 countries: a joinpoint regression analysis of global trends. Endocrine. 2023;80(2):355–65. - PubMed
-
- Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9(4):225–34. - PubMed
-
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid: Official J Am Thyroid Association. 2016;26(1):1–133. - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials